You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Raw chart and full-history price indicators begin at the captured split on Sep 29, 2020; bars on opposite sides are not compared.
Loras Labs reported Q2 total income from operations of 2,206 crore and a 34.5% EBITDA margin; small molecule CDMO sales grew 86% to 875 crores, affordable medicines revenue grew 15% to 1,302 crores, and peptide capacity was over 16,000 liters.
Illustrative technical + ownership context — a signal mix, not investment advice.
Raw-price comparisons begin at the captured split on Sep 29, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBOM:LAURUSLABS | +2.1% | +17.6% | +77.3% | +0.1% | +116.1% |
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-11-06 | 1.00 INR |
| 2026-05-08 | 1.20 INR |
| 2025-10-31 | 0.80 INR |
| 2025-05-09 | 0.80 INR |
| 2024-11-06 | 0.40 INR |
| 2024-05-08 | 0.40 INR |
| 2023-11-02 | 0.40 INR |
| 2023-05-10 | 1.20 INR |
| 2022-11-03 | 0.80 INR |
| 2022-05-10 | 1.20 INR |
| 2021-11-17 | 0.80 INR |
| 2021-05-11 | 0.80 INR |
| 2021-02-08 | 0.40 INR |
| 2020-11-10 | 0.80 INR |
| 2020-07-01 | 0.20 INR |
| 2020-03-23 | 0.30 INR |
| 2019-07-03 | 0.30 INR |
| 2018-06-28 | 0.30 INR |
| 2017-07-06 | 0.30 INR |
No upcoming investor events are listed for this company yet.
